Semaglutide vs Tirzepatide: Which One Actually Wins for Weight Loss
Ozempic versus Mounjaro. Wegovy versus Zepbound. People have been asking which GLP-1 medication is better since tirzepatide launched, but until recently there was no clean answer because no one had tested them directly against each other. SURMOUNT-5 changed that. Published in the New England Journal of Medicine, it enrolled 751 adults with obesity and no type 2 diabetes, then randomized them to tirzepatide or semaglutide at maximum tolerated doses for 72 weeks. This is the first real head to head comparison, and the gap between the two drugs is both real and large. The full picture, however, is more interesting than a single weight loss number.
The First Real Head to Head: What SURMOUNT-5 Tested
For years the semaglutide versus tirzepatide debate ran on indirect comparisons. Researchers lined up results from separate trials and tried to guess which drug was stronger, but the populations, protocols, and timeframes never matched cleanly. That guesswork ended with SURMOUNT-5. The trial enrolled 751 adults with obesity who did not have type 2 diabetes and randomized them one to one to either tirzepatide or semaglutide, each titrated to its maximum tolerated dose over 72 weeks. Because both drugs were pushed to their ceiling in the same population at the same time, the result is a genuine apples to apples comparison rather than a statistical estimate. The mechanistic background explains why scientists expected a difference. Semaglutide mimics one gut hormone, GLP-1, to reduce appetite and slow digestion. Tirzepatide mimics two hormones, GLP-1 and GIP. That second pathway was the entire reason researchers predicted tirzepatide would pull ahead, because it adds insulin sensitivity and energy expenditure effects that single hormone therapy cannot reach. SURMOUNT-5 was designed to find out whether that theoretical edge translated into real world weight loss. As the chart shows, the two weight loss curves separate within the first couple of months and never converge, which tells you the difference is structural rather than a short term fluctuation.
Mean Body Weight Loss Over 72 Weeks (SURMOUNT-5)
Both drugs work, but the curves separate early and keep diverging. At 72 weeks tirzepatide reached 20.2 percent average weight loss versus 13.7 percent for semaglutide at maximum tolerated doses.
- Tirzepatide
- Semaglutide
The Headline Numbers and Who Reaches Each Milestone
At 72 weeks the difference between the two drugs was not subtle. Patients on tirzepatide lost an average of 20.2 percent of their body weight, while patients on semaglutide lost 13.7 percent. That works out to 47 percent more relative weight loss with tirzepatide, a margin that would have seemed impossible from a once weekly injection only five years ago. For someone starting at 220 pounds, the tirzepatide average translates to roughly 44 pounds lost. The milestone data is where the gap becomes most tangible. Reaching a 10 percent weight loss threshold happened for 83.9 percent of tirzepatide patients versus 67.2 percent on semaglutide. At the 20 percent threshold the split widened to 51.8 percent versus 30.1 percent. At the most demanding 25 percent milestone, 31.6 percent of tirzepatide patients got there compared with only 16.1 percent on semaglutide. In plain terms, nearly one in three people on tirzepatide lost a quarter of their body weight, while only one in six reached that mark on semaglutide. These are not rounding errors. They represent fundamentally different odds of hitting the outcomes most patients actually care about, and they hold up across the full range of weight loss targets rather than at a single cherry picked point.
Patients Reaching Weight Loss Milestones (SURMOUNT-5)
Nearly 1 in 3 people on tirzepatide lost 25 percent or more of their body weight, roughly double the proportion seen with semaglutide at the same milestone.
- Tirzepatide
- Semaglutide
Blood Sugar Control: The Same Story on Glucose
Weight loss is only half of what these drugs do. For patients with type 2 diabetes, blood sugar control matters just as much, and here the pattern repeats. The SURPASS-2 trial compared the two medications head to head on HbA1c reduction, the standard measure of long term blood sugar control, and tirzepatide outperformed semaglutide at every dose tested. At the highest dose, tirzepatide 15mg produced a 2.46 percent reduction in HbA1c. Tirzepatide 10mg delivered a 2.24 percent reduction. Semaglutide at 1mg, its standard comparison dose, produced a 1.86 percent reduction. The dual GLP-1 and GIP mechanism simply hits glucose harder than single hormone activation. The combined outcome data is even more striking. At the highest tirzepatide dose, 60 percent of patients reached good blood sugar control and at least 10 percent weight loss at the same time. On semaglutide at comparable doses, only 22 percent of patients reached that combined target. For a patient managing both obesity and diabetes, that combination of metabolic wins is the entire goal of treatment, and the gap in who achieves it is large enough to shape real prescribing decisions rather than being a statistical footnote.
HbA1c Reduction by Drug and Dose (SURPASS-2)
In patients with type 2 diabetes, tirzepatide outperformed semaglutide on blood sugar control at every dose. The dual GLP-1 and GIP mechanism hits glucose harder.
- HbA1c Reduction (%)
Side Effects, Cost, and the Full Comparison
If tirzepatide wins on efficacy, the natural worry is that it must come with worse side effects. The data does not support that fear. Gastrointestinal side effects like nausea, vomiting, and diarrhea are essentially a feature of the entire drug class. Both medications cause them, both are worst during dose escalation, and both tend to settle down over time. In SURMOUNT-5, the rate of GI side effects severe enough to cause discontinuation was actually lower for tirzepatide at 2.7 percent than for semaglutide at 5.6 percent, an unexpected finding given tirzepatide's stronger effects. Cost cuts in an equally surprising direction. In the United States without insurance, tirzepatide lists at roughly 1,000 dollars per month while semaglutide lists at roughly 1,350 dollars per month, so the more effective drug is also the cheaper one at list price. Looking across the full scorecard, tirzepatide leads on average weight loss, on the share of patients reaching 25 percent loss, on HbA1c reduction, on waist circumference change, and on GI tolerability. Semaglutide holds one decisive advantage that efficacy numbers do not capture, which the next section addresses directly. Both drugs were approved by the FDA for obesity, semaglutide in 2021 and tirzepatide in 2023.
The Catch Nobody Likes: Weight Returns When You Stop
Before anyone treats tirzepatide as a clean victory, two important caveats deserve equal weight. The first is cardiovascular outcomes. Semaglutide has already played a major ace through the SELECT trial, which showed a 20 percent reduction in major cardiovascular events among people with existing heart disease and obesity. That is a hard clinical outcome, an actual reduction in heart attacks and strokes, not a number on a scale. Tirzepatide's cardiovascular outcome trial is still ongoing, so for any patient with established heart disease, semaglutide remains the better supported choice until that data arrives. The second caveat applies to both drugs equally. These are chronic therapies, not short courses. After stopping semaglutide, patients regain roughly 67 percent of their lost weight within a year, and tirzepatide shows a similar pattern in the range of 50 to 70 percent. This is not a defect unique to either medication. It is the direct consequence of the mechanism, because these drugs suppress appetite by supplementing a hormone, and when you stop taking them the appetite returns. The biology was never changed, only the pharmacology was borrowed. Planning around long term access and cost is therefore not optional, and that conversation belongs at the prescription stage rather than months later when the weight starts coming back.
Weight Regained Within 12 Months of Stopping
Weight regain is a class wide feature, not a flaw unique to either drug. After discontinuation, most patients regain the majority of lost weight because appetite suppression ends when the medication stops.
- Weight Regained (%)
The Verdict: Which One Should You Be On
There is no single winner that fits every patient, but the decision framework is now clear. If maximum weight loss is your primary goal and you do not have existing cardiovascular disease, tirzepatide has the stronger efficacy data by a real margin, and as a bonus it carries a lower list price and a lower GI discontinuation rate. The 47 percent greater relative weight loss is not a marketing claim, it is a head to head trial result. If cardiovascular risk is your main concern, semaglutide has published hard outcome data that tirzepatide cannot yet match. The 20 percent reduction in cardiovascular events from the SELECT trial is exactly the kind of evidence that matters for a patient with a prior heart attack, and it would be a mistake to trade that proven protection for additional scale weight loss. Regardless of which drug you and your physician choose, plan for long term use, because most of the weight returns when treatment stops. Neither medication is a magic solution, both require sustained commitment, and both work dramatically better than lifestyle intervention alone. The right move is to talk through these tradeoffs with your doctor rather than reaching a conclusion from a social feed.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
16:8 Fasting Loses About the Same Weight as Counting Calories. The Early Window and the Muscle Question Are What Actually Differ.
In four randomized trials, an 8-hour eating window produced between 2.3 kg more and 0.8 kg less weight loss than its comparison diet. The 12-month NEJM trial found no significant edge over calorie restriction. An early 7 am to 3 pm window did better, and one trial in trained men saw testosterone fall. An educational review of the time-restricted eating evidence for men.
A 20-Second Squeeze Test Predicted Death Better Than Blood Pressure in 139,691 People Across 17 Countries. Every 5 kg of Grip Strength a Man Loses Adds 16 Percent to His Mortality Risk, and It Is Measured in Almost No Physical.
In the PURE study of 139,691 adults in 17 countries, each 5 kg drop in grip strength was associated with a 16 percent higher risk of death from any cause and a 17 percent higher risk of cardiovascular death, and grip predicted mortality more strongly than systolic blood pressure. UK Biobank reproduced the finding in 502,293 people. Men peak at roughly 51 kg in their thirties, cross the 27 kg sarcopenia threshold in their eighties if nothing changes, and lose strength faster on GLP-1 medications unless they train. An educational review of what grip strength measures, why it predicts survival, what testosterone and resistance training do to it, and where the evidence stops.
The Least Fit Fifth of 122,007 Patients Died at Five Times the Rate of the Fittest. Being Out of Shape Carried More Risk Than Smoking, Diabetes or Heart Disease, and Almost Nobody Measures It.
In a Cleveland Clinic study of 122,007 adults followed for a median of 8.4 years, low cardiorespiratory fitness carried a hazard ratio of 5.04 for death versus elite fitness, larger than smoking (1.41), diabetes (1.40) or coronary disease (1.29). A 750,302-veteran cohort found a fourfold gap and no upper limit to the benefit. VO2 max falls 3 to 6 percent a decade in the thirties and more than 20 percent a decade after 70, and 8 weeks of interval training can recover about 7 percent. An educational review of what cardiorespiratory fitness means for men, how it interacts with testosterone and GLP-1 weight loss, and why the causal question is still open.